In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on CervoMed, with a price target of $20.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Soumit Roy has given his Buy rating due to a combination of factors surrounding CervoMed’s strategic advancements and clinical trial developments. The company is poised to initiate a pivotal Phase 3 trial for neflamapimod in dementia with Lewy bodies (DLB) by the second half of 2026, following alignment with the FDA and anticipated feedback from global regulators. This trial is expected to enroll approximately 300 patients, with significant trial design details, including dosing regimens, to be disclosed in early 2026.
Additionally, CervoMed’s ongoing Phase 2 trial is set to provide initial safety, biomarker, and pharmacokinetic data by the fourth quarter of 2025, which could further validate the efficacy of neflamapimod. The company’s approach to exclude patients with Alzheimer’s disease co-pathology ensures a more targeted study population, potentially enhancing the trial’s outcomes. These strategic steps, coupled with the company’s financial management, underpin the positive outlook reflected in the Buy rating.
According to TipRanks, Roy is an analyst with an average return of -17.3% and a 26.41% success rate. Roy covers the Healthcare sector, focusing on stocks such as Protara Therapeutics, CervoMed, and Cullinan Management.
In another report released today, Roth MKM also maintained a Buy rating on the stock with a $19.00 price target.